<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mutations in laminin-alpha2 cause a severe <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo>, called <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDC1A</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The two main receptors that interact with laminin-alpha2 are dystroglycan and alpha7beta1 integrin </plain></SENT>
<SENT sid="2" pm="."><plain>We have previously shown in mouse models for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDC1A</z:e> that muscle-specific overexpression of a miniaturized form of agrin (mini-agrin), which binds to dystroglycan but not to alpha7beta1 integrin, substantially ameliorates the disease (Moll, J., P </plain></SENT>
<SENT sid="3" pm="."><plain>Barzaghi, S </plain></SENT>
<SENT sid="4" pm="."><plain>Lin, G </plain></SENT>
<SENT sid="5" pm="."><plain>Bezakova, H </plain></SENT>
<SENT sid="6" pm="."><plain>Lochmuller, E </plain></SENT>
<SENT sid="7" pm="."><plain>Engvall, U </plain></SENT>
<SENT sid="8" pm="."><plain>Muller, and M.A </plain></SENT>
<SENT sid="9" pm="."><plain>Ruegg </plain></SENT>
<SENT sid="10" pm="."><plain>2001 </plain></SENT>
<SENT sid="11" pm="."><plain>Nature </plain></SENT>
<SENT sid="12" pm="."><plain>413:302-307; Bentzinger, C.F., P </plain></SENT>
<SENT sid="13" pm="."><plain>Barzaghi, S </plain></SENT>
<SENT sid="14" pm="."><plain>Lin, and M.A </plain></SENT>
<SENT sid="15" pm="."><plain>Ruegg </plain></SENT>
<SENT sid="16" pm="."><plain>2005 </plain></SENT>
<SENT sid="17" pm="."><plain>Matrix Biol </plain></SENT>
<SENT sid="18" pm="."><plain>24:326-332.) </plain></SENT>
<SENT sid="19" pm="."><plain>Now we show that <z:hpo ids='HP_0003584'>late-onset</z:hpo> expression of mini-agrin still prolongs life span and improves overall health, although not to the same extent as early expression </plain></SENT>
<SENT sid="20" pm="."><plain>Furthermore, a chimeric protein containing the dystroglycan-binding domain of perlecan has the same activities as mini-agrin in ameliorating the disease </plain></SENT>
<SENT sid="21" pm="."><plain>Finally, expression of full-length agrin also slows down the disease </plain></SENT>
<SENT sid="22" pm="."><plain>These experiments are conceptual proof that linking the basement membrane to dystroglycan by specifically designed molecules or by endogenous ligands, could be a means to counteract <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDC1A</z:e> at a progressed stage of the disease, and thus opens new possibilities for the development of treatment options for this <z:hpo ids='HP_0003560'>muscular dystrophy</z:hpo> </plain></SENT>
</text></document>